Medicine Description vilatriplo 25/62.5/100 mcg
Vilatriplo Inhalation Capsules is an innovative oral inhalation therapy system designed to provide effective control of the symptoms of both asthma and chronic obstructive pulmonary disease (COPD), two chronic respiratory conditions that affect millions of people worldwide. This product features a unique formulation that includes a pack containing two different types of hard capsules, the contents of which are inhaled using a special inhaler. This approach enables the delivery of different active ingredients to the lungs to achieve integrated therapeutic effects.
The active ingredients in Vilatriplo Inhalation Capsules
A pack of Vilatriplo Inhalation Capsules consists of six equally divided strips:
Three strips containing fluticasone furoate 100 mcg per capsule: Fluticasone furoate is a potent corticosteroid with an anti-inflammatory effect that is inhaled directly into the lungs. It works by reducing swelling and irritation in the airways, helping to prevent asthma attacks and reduce the symptoms of COPD. Three strips containing a combination of two bronchodilator agents:
Umeclidinium 62.5 mcg per capsule: Umeclidinium is a long-acting anticholinergic (LAMA). It works by blocking the action of a chemical called acetylcholine in the lungs, causing the muscles surrounding the airways to relax and widen, thus facilitating airflow.
Vilanterol 25 mcg per capsule: Vilanterol is a long-acting beta-2 agonist (LABA). It works by binding to beta-2 receptors in the lungs, stimulating the relaxation and widening of the smooth muscles in the airways, providing a long-lasting bronchodilator effect.
Available Strengths
The specific strengths available in the Vilatriplo inhalation capsule pack are fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg per inhalation dose. This treatment regimen provides a specific combination of these three active ingredients. Indications for Use of Vilatriplo Inhalation Capsules
Vilatriplo Inhalation Capsules are used to treat:
Asthma: As a long-term daily preventative treatment to control the symptoms of chronic asthma in adults. Fluticasone furoate helps reduce the underlying inflammation in the airways, while the combination of umeclidinium and vilanterol provides bronchodilation to help prevent shortness of breath, wheezing, and coughing.
Chronic Obstructive Pulmonary Disease (COPD): As a long-term daily maintenance treatment to improve lung function, reduce symptoms such as shortness of breath, cough, and sputum production, and reduce the risk of exacerbations in adults with COPD.